Biogen Idec To Present Data From Hematology Programs, Including ELOCTATE™ And ALPROLIX® At American Society of Hematology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) will present data supporting its approved hemophilia therapies at the 56th Annual Meeting of the American Society of Hematology (ASH) taking place in San Francisco, December 6-9. The company will present seven abstracts, including two oral presentations, demonstrating its ongoing commitment to advance innovative science in hematology, with the goal of addressing significant clinical needs and improving patient care.

Help employers find you! Check out all the jobs and post your resume.